Table 3.

Impact of liver dysfunction on anti-TB treatment in the study groups

Changes of anti-TB treatment	Scheduled monitoring group (n = 111)	Passive detection group (n = 162)
No change	72 (64.9%)	70 (43.2%)
Interruption	15 (13.5%)	48 (29.6%)
Dose decrease	4 (3.6%)	1 (0.6%)
Drug replacement	6 (5.4%)	11 (6.8%)
Discontinuation	2 (1.8%)	10 (6.2%)
Changes in medical administration	3 (2.7%)	11 (6.8%)
Interruption with drug replacement	7 (6.3%)	9 (5.6%)
Interruption with change in medical administration	1 (0.9%)	1 (0.6%)
Dose decrease with change in medical administration	1 (0.9%)	0 (0.0%)
Change in medical with discontinuation	0 (0.0%)	1 (0.6%)